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Background. Enteric fever can lead to prolonged hospital stays, clinical complications, and death. The Surveillance for Enteric 
Fever in Asia Project (SEAP), a prospective surveillance study, characterized the burden of enteric fever, including illness severity, in 
selected settings in Bangladesh, Nepal, and Pakistan. We assessed disease severity, including hospitalization, clinical complications, 
and death among SEAP participants.
Methods. We analyzed clinical and laboratory data from blood culture–confirmed enteric fever cases enrolled in SEAP hospitals 
and associated network laboratories from September 2016 to September 2019. We used hospitalization and duration of hospital stay 
as proxies for severity. We conducted a follow-up interview 6 weeks after enrollment to ascertain final outcomes.
Results. Of the 8705 blood culture-confirmed enteric fever cases enrolled, we identified 6 deaths (case-fatality ratio, .07%; 95% 
CI, .01–.13%), 2 from Nepal, 4 from Pakistan, and none from Bangladesh. Overall, 1.7% (90/5205) of patients recruited from SEAP 
hospitals experienced a clinical complication (Bangladesh, 0.6% [18/3032]; Nepal, 2.3% [12/531]; Pakistan, 3.7% [60/1642]). The 
most identified complications were hepatitis (n = 36), septic shock (n = 22), and pulmonary complications/pneumonia (n = 13). 
Across countries, 32% (2804/8669) of patients with hospitalization data available were hospitalized (Bangladesh, 27% [1295/4868]; 
Nepal, 29% [455/1595]; Pakistan, 48% [1054/2206]), with a median hospital stay of 5 days (IQR, 3–7).
Conclusions. While defined clinical complications and deaths were uncommon at the SEAP sites, the high proportion of hospi-
talizations and prolonged hospital stays highlight illness severity and the need for enteric fever control measures, including the use 
of typhoid conjugate vaccines.
Keywords.  enteric fever; typhoid; severity; mortality; antimicrobial resistance.
Enteric fever (typhoid and paratyphoid fevers), caused by 
Salmonella enterica serovars Typhi (S. Typhi) and Paratyphi 
A, B, and C (S. Paratyphi), remains an important public health 
problem in lower-income countries, especially in South Asia 
and sub-Saharan Africa [1, 2]. Typhoid fever is estimated to 
cause approximately 11 million illnesses and 116  800 deaths 
globally, while paratyphoid fever is estimated to cause 3.4 
million illnesses and 19  100 deaths [2]. S. Typhi is the most 
common bloodstream infection in South Asia [3], the region 
that accounts for almost 70% of the global enteric fever burden 
and mortality [2].
Before the widescale implementation of antibiotics, an esti-
mated 10–15% of patients with enteric fever developed clinical 
complications, the most severe including intestinal perforation, 
gastrointestinal bleeding, and neurological complications [4]. 
Other complications such as hepatitis, pneumonia, myocarditis, 
and cholecystitis are well described [5]; however, there is a pau-
city of recent data on the spectrum and frequency of clinical 
complications [6, 7].
Additionally, determining the case fatality remains difficult 
for several reasons [7]. Global disease burden and mortality es-
timations have typically relied on available data from multiple 
sources; however, methodological differences, varying sample 
sizes, and the use of different confirmatory tests limit the ability 
to pool data across various studies. Existing reports of case fa-
tality range from 0% to 23% depending on the geographic loca-
tion and surveillance method used [6–9]. The most commonly 
estimated case-fatality ratio is 1% [10], although estimates are 
higher among those infected with multidrug-resistant strains 
and differ among age groups and regions [4, 7–9, 11].
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Recent data suggest a decline in enteric fever mortality, likely 
due to improvements in clinical capacity and access to effective 
treatments in endemic countries [8]. Updated mortality esti-
mates, rates of complications, and severity data are necessary 
to understand the burden of severe typhoid and inform health 
policy, especially with growing antimicrobial resistance [7, 12]. 
The Surveillance for Enteric Fever in Asia Project (SEAP), a 
multicountry, prospective, population-based surveillance pro-
ject, was established to characterize the burden of enteric fever 
in Bangladesh, Nepal, and Pakistan [13]. Here, we describe ill-
ness severity, including hospitalization, duration of hospital 
stays, clinical complications, and deaths, among blood culture–




We conducted clinical and laboratory surveillance for enteric 
fever from September 2016 to September 2019 at selected hos-
pitals and through enhanced laboratory surveillance at addi-
tional participating hospitals and clinics (laboratory network 
sites) that provide both outpatient and inpatient services. 
SEAP sites in Dhaka, Bangladesh, included 2 large pediatric 
hospitals and 3 laboratories (serving both adult and pediatric 
populations); in Nepal, 1 hospital in Kathmandu and 1 in 
Kavrepalanchok, plus 8 laboratories; and in Karachi, Pakistan, 
2 tertiary hospitals, 3 laboratories, and surgical wards in 2 ad-
ditional hospitals. Study site selection was described previously; 
in brief, Bangladesh, Nepal, and Pakistan were selected as coun-
tries with a known burden of enteric fever. A review of health 
facilities and laboratories led to the inclusion of several sites in 
each country that had existing evidence of enteric fever burden, 
the microbiological infrastructure to identify enteric fever by 
blood culture, inpatient and outpatient facilities, and the ability 
to obtain population-based sociodemographic data of the fa-
cility catchment area [14].
Definitions
Complications were defined as a diagnosis of a comorbid 
condition confirmed by the treating physician as a compli-
cation of enteric fever. Hospital admission and duration of 
hospital stay were used as proxies for disease severity. We de-
fined a hospitalization day as one that included an overnight 
stay. Fluoroquinolone resistance included reduced suscepti-
bility to ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, 
and gatifloxacin. Third-generation cephalosporin resist-
ance included resistance to ceftriaxone, cefixime, cefotaxime, 
cefpodoxime, and ceftazidime. Extensively drug-resistant 
(XDR) S. Typhi is characterized as resistant to first-line anti-
biotics (chloramphenicol, ampicillin, and trimethoprim-
sulfamethoxazole), fluoroquinolones, and third-generation 
cephalosporins [12].
Inclusion Criteria
We selected patients with blood culture–confirmed Typhi or 
Paratyphi A of any age who (1) presented to outpatient depart-
ments, were identified in inpatient/surgical wards, or identi-
fied through hospital laboratories at SEAP hospitals or (2) were 
identified at laboratory network sites. Inclusion criteria by en-
rollment location are described in Table 1.
Data Collection
Study teams reviewed the medical charts of all participants 
from SEAP hospitals at the time of the enrollment visit and col-
lected data on patient age, medications prescribed, duration of 
hospital admission for those hospitalized, complications, and 
clinical outcomes. Medical charts from laboratory network pa-
tients were not available for review. To ascertain final patient 
outcomes (eg, resolved, died), study teams attempted to con-
tact all patients with blood culture–confirmed enteric fever en-
rolled in the study by telephone by calling up to 5 times over 
a 2-week period beginning 6 weeks following enrollment. The 
study teams also collected phone numbers of family members 
to contact if the patient could not be reached directly. If a pa-
tient sought medical care related to his or her illness during the 
6 weeks between enrollment and follow-up, study teams at-
tempted to obtain medical records from those visits to perform 
chart reviews.
Statistical Analysis
We calculated frequencies of complications and outcomes. 
We conducted bivariate comparisons using Pearson’s 
Table 1. Inclusion Criteria by Enrollment Location for the Surveillance for Enteric Fever in Asia Project (SEAP)
Enrollment Location Inclusion Criteria
Outpatient department A patient presenting to the outpatient department (including emergency department) with a self-reported history of fever 
for ≥3 consecutive days within the last 7 days and living within the defined catchment area
Inpatient department A patient admitted to the hospital with a clinical suspicion or a confirmed diagnosis of enteric fever at any time during 
hospitalization
Hospital laboratory A patient with blood culture–confirmed Salmonella Typhi or Paratyphi A
Surgical department A patient with a nontraumatic ileal perforation, even in the absence of laboratory confirmation, with no other known etiology
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chi-square test and used the Wilcoxon rank-sum test for as-
sessing the differences in the median values of continuous 
variables.
Country-specific univariable and multivariable logistic re-
gression models were used to identify potential predictors of 
hospitalization among cases identified from the SEAP sites, 
including age, gender, serovar (S. Typhi or S. Paratyphi A), 
fluoroquinolone resistance, third-generation cephalosporin re-
sistance, prior antibiotic use, and time in days from fever onset 
to hospital presentation. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were estimated from the models.
Similarly, country-specific univariable and multivariable 
negative binomial regression models were used to identify pre-
dictors of the duration of hospital stay among patients hospi-
talized at the SEAP hospitals, including the same predictors 
stated above and empiric treatment at hospital presentation. 
Relative risks and 95% CIs were estimated from the models. For 
all analyses, a P value less than .05 was considered statistically 
significant.
Ethical Considerations
Informed consent was obtained from all participants or parents/
guardians of participants, as well as verbal assent from partici-
pants aged 11–17 years old. The study protocol was approved 
by the Bangladesh Institute of Child Health Ethical Review 
Committee, Nepal Health Research Council Ethical Review 
Board, Pakistan Ethical Review Committee, and Stanford 
University Institutional Review Board. This project was ap-
proved by the Centers for Disease Control and Prevention 
(CDC) human subjects review as research with CDC not di-
rectly engaged, so a full institutional review board approval was 
not required.
RESULTS
A total of 34  748 patients were enrolled from SEAP sites in 
Bangladesh, Nepal, and Pakistan, of whom 8705 (25%) were 
blood culture–confirmed for enteric fever; 5215 (60%) cases 
were identified from the SEAP hospitals and 3490 (40%) cases 
were identified through laboratory network sites. Of the con-
firmed cases, 7591 (87%) were positive for S. Typhi and 1114 
(13%) were positive for S. Paratyphi A (Table 2). There was no 
laboratory evidence of bacterial coinfection among the blood 
culture–confirmed cases.
Clinical Complications
Over 99% (5205/5215) of the patients identified from SEAP 
hospitals had medical records available for review, of whom 
90 of 5205 (1.7%) experienced at least 1 complication during 
the enrollment visit (Bangladesh, 0.6 % [18/3032]; Nepal, 2.3% 
[12/531]; Pakistan, 3.7% [60/1642]). Seventeen (19%) patients 
developed more than 1 complication. Complications included 
hepatitis (n = 36), septic shock (n = 22), pulmonary complica-
tions/pneumonia (n = 13), encephalopathy (n = 12), intestinal 
perforation (n = 10), gastrointestinal bleeding (n = 9), intestinal 
Table 2. Characteristics of Patients Enrolled in the Surveillance for Enteric Fever in Asia Project (SEAP)—Bangladesh, Nepal, and Pakistan, 2016–2019
Bangladesh Nepal Pakistan Total
Patients enrolled, n 17 441 7215 10 092 34 748
Blood culture–confirmed enteric fevera cases, n (%) 4873 (28) 1602 (22) 2230 (22) 8705 (25)
 Patients identified from SEAP hospitals,b n (%) 3032 (62) 534 (33) 1649 (74) 5215 (60)
 S. Typhi, n (% of culture-confirmed cases) 4131 (85) 1367 (85) 2093 (94) 7591 (87)
 Age in years, median (IQR) 6 (3–14) 20 (15–25) 6 (3–13) 8 (4–19)
 Male gender, n (%) 2754 (57) 942 (59) 1286 (58) 4982 (57)
 Days from fever onset to hospital presentation, median (IQR) 5 (3–6) 4 (3–7) 6 (4–10) 5 (3–7)
 Antibiotic use prior to enrollment visit, n (%) 1651 (34) 390 (24) 1292 (58) 3333 (38)
 Hospitalization data available, n (%) 4868 (>99) 1595 (>99) 2206 (99) 8669 (>99)
  Hospitalized, n (%) 1295 (27) 455 (29) 1054 (48) 2804 (32)
  Age in years, median (IQR) 5 (3–10) 19 (14–24) 6 (3–13) 7 (3–16)
  Male gender, n (%) 733 (57) 238 (52) 618 (59) 1589 (57)
  Days from fever onset to hospital presentation, median (IQR) 6 (4–7) 5 (4–8) 8 (5–13) 6 (4–9)
  Antibiotic use prior to enrollment visit, n (%) 561 (43) 141 (31) 689 (65) 1391 (50)
  Duration of hospital admission in days, median (IQR) 6 (5–9) 6 (4–8) 3 (2–5) 5 (3–7)
   S. Typhi infection, median (IQR) 7 (5–9) 6 (4–8) 3 (2–5) 5 (3–7)
   S. Paratyphi A infection, median (IQR) 6 (5–8) 4 (4–6) 3 (2–3) 5 (3–7)
 Participated in follow-up interview, n (% of culture-confirmed cases) 4562 (94) 1498 (94) 2029 (91) 8089 (93)
  Additional symptoms reported, n (%) 346 (8) 265 (18) 105 (5) 716 (9)
   Sought additional medical care, n (%) 251 (73) 135 (51) 69 (66) 455 (64)
N = 34 748. 
Abbreviation: IQR, interquartile range.
aSalmonella Typhi and Paratyphi A.
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obstruction (n = 6), renal impairment (n = 1), and myocarditis 
(n = 1). Intestinal obstructions were secondary complications 
only among patients who experienced an intestinal perforation. 
Patients infected with S. Typhi who reportedly consumed anti-
biotics before hospitalization and those who took a longer time 
to seek care were more likely to be diagnosed with a complica-
tion (Table 3).
Six-Week Follow-up
Of the 8705 confirmed cases, 3 died during hospitalization. Of 
the remaining 8702 patients, 8092 (93%) patients or patient 
caregivers participated in the follow-up interview at 6 weeks: 
Bangladesh, 94% (4562/4873); Nepal, 94% (1498/1602); and 
Pakistan, 91% (2029/2230). Study teams were unable to inter-
view 610 (7%) patients; 9 refused to participate and the others 
could not be reached. In Pakistan, 64% of patients with typhoid 
with known outcomes were infected with strains resistant to 
third-generation cephalosporins, as were 71% of those lost to 
follow-up and 100% of the fatal cases (Table 4).
A total of 9% (716/8092) of participants contacted reported 
symptoms following the enrollment visit; 64% (455/716) sought 
additional medical care (Table 2), and 69% (313/455) of those 
patients had medical records available for review. One patient 
was diagnosed with an intestinal perforation 1  day following 
the hospital outpatient visit, an 18-year-old male from Pakistan 
with XDR typhoid.
Case-fatality Ratio
Of the 8095 participants with known outcomes (including the 
3 who died during hospitalization), we identified 6 deaths, all 
culture-positive for S. Typhi (overall case-fatality ratio of .07%; 
95% CI, .01–.13%). Two fatal cases occurred in Nepal, both 
adult males (33 and 65 years old) who presented to laboratory 
network sites and reportedly died after hospital discharge. Four 
fatal cases occurred in Pakistan, 2 male and 2 female patients 
(8  months–8  years old). Three of these patients died at the 
SEAP hospitals during hospitalization and 1 died after the en-
rollment visit. No deaths were identified in Bangladesh. None of 
the fatal cases included a diagnosis of intestinal perforations. In 
Pakistan, 3 patients who died reportedly consumed antibiotics 
prior to enrollment. All isolates from fatal cases were resistant 
to fluoroquinolones, and those in Pakistan were all XDR.
Hospitalization data were available for 8062 of 8095 patients 
with known outcomes. Five of the 2605 hospitalized patients 
died (case-fatality ratio of .19%; 95% CI, .02–.36%). One pa-
tient enrolled as an outpatient (1/5457) died (case-fatality ratio 
of .02%; 95% CI, 0–.5%).
Hospitalization
Of the 8669 patients with confirmed enteric fever with available 
hospitalization data, 2804 (32%) were hospitalized. Overall, 
2576 (92%) of the hospitalized patients with confirmed enteric 
fever were infected with S. Typhi (Bangladesh, 89% [1155/1295]; 
Nepal, 89% [404/455]; Pakistan, 96% [1017/1054]). Among pa-
tients infected with S. Typhi, the highest proportion of hospi-
talizations occurred among children younger than 2 years old 
in Bangladesh and Nepal and among those 16 years or older in 
Pakistan. Across countries, the highest proportion of hospital-
izations among those with S. Paratyphi A infection was among 
children younger than 5 years old (Figure 1).
Infection with S. Typhi, reported prior antibiotic use, and 
delayed care-seeking were significant common predictors of 
Table 3. Characteristics of Patients With Blood Culture–Confirmed Enteric Fever (Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for 
Enteric Fever in Asia Project (SEAP) With Clinical Complications Documented in the Medical Records—Bangladesh, Nepal, and Pakistan, 2016–2019












Demographics       
 Age, median (IQR), years 5 (3–8) 19 (14–25) 9 (3–17) 9 (4–17) 6 (3–10) <.001
 Male gender, n (%) 8 (44) 8 (67) 36 (60) 52 (58) 2880 (56) .78
Isolate characteristics       
 S. Typhi serovar, n (%) 17 (94) 12 (100) 58 (97) 87 (97) 4516 (88) .01
 Fluoroquinolone resistance, n (%) 18 (100) 8 (67) 60 (100) 86 (96) 4902 (96) .82
 S. Typhi third-generation cephalosporin 
resistance,a n (%)
46 (79) 0 (0) 0 (0) 46 (79) 932 (63) .01
Severity       
 Time from fever onset to hospital presentation, 
median (IQR), days
6 (3–8) 5 (3–8) 10 (7–16) 8 (5–14) 5 (3–7) <.001
 Prior antibiotic use,b n (%) 8 (44) 8 (67) 53 (88) 69 (77) 2679 (52) <.001
N = 5205. 
Abbreviation: IQR, interquartile range. 
aPakistan only, where antibiotic resistance testing results were available: n = 58 with complication, n = 1470 without complications; no third-generation cephalosporin resistance was de-
tected in Bangladesh or Nepal. 
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hospitalization across countries in the univariable models. In 
the multivariable models, there was a consistent trend in the 
direction of the effect for Typhi infection and prior antibiotic 
use, which was statistically significant in 2 of the 3 countries. 
Resistance to fluoroquinolones and third-generation cephalo-
sporins was associated with higher odds of hospitalization in 
Pakistan (Table 5).
Data on duration of hospital stay were available for 
96% (1911/1981) of patients admitted to SEAP hospitals 
(Bangladesh, 939/940; Nepal, 150/150; Pakistan 822/891). The 
median duration of hospital stay was the same for patients with 
Typhi and Paratyphi A, 5 days (interquartile range, 3–7 days) 
(Table  2). There were no common predictors for duration of 
hospital stay across countries. Third-generation cephalosporin 
resistance was associated with 48–54% longer hospital stays in 
Pakistan (Table 6).
DISCUSSION
The SEAP study generated comprehensive data on illness se-
verity and outcomes among a large cohort of blood culture–
confirmed cases of enteric fever from high-burden settings in 
Bangladesh, Nepal, and Pakistan. These data are important for 
understanding the burden of severe typhoid, and the burden 
that enteric fever places on the healthcare system. This is partic-
ularly relevant in settings like South Asia where many severely 
ill patients are refused admission due to hospital capacity lim-
itations [15].
Mortality is a critical measure of disease severity and is the 
main driver of typhoid disease burden estimates. A recent meta-
analysis estimated the overall case fatality of enteric fever to be 
2.49% [9]. While this is markedly higher than the case-fatality 
ratio identified from SEAP, several of the studies included in 
the meta-analysis with higher case-fatality rates utilized small 
sample sizes or included studies from as early as 1960. The 
2017 Global Burden of Disease Study estimated an overall case-
fatality rate of 0.95%, with the South Asia–specific estimates 
closer to 1.1% [2]. The widely invoked case-fatality ratio of 1% 
was estimated using published data from hospital-based studies 
and separate community-based studies [10]. Because enteric 
fever is generally treated as an outpatient disease, estimates 
derived from inpatient surveillance exclude mild cases not ad-
mitted to the hospital and may overestimate the case-fatality 
ratio [16–19]. However, active surveillance at the community 
level detects and treats disease early, providing very limited in-
formation on uncommon outcomes like severe complications 
and death [16, 20]. We observed such variation in mortality in 
the SEAP data, in which the case-fatality ratio among inpatients 
was almost 10 times higher than that of outpatients.
Alternatives to the tertiary hospitals in the SEAP settings 
are laboratory network sites, data from which are often not in-
cluded in hospital-based surveillance. These facilities include 
community-based private consultation centers, clinics, and 
secondary hospitals, and constitute an important component 
of a comprehensive enteric fever surveillance system [19]. By 
Table 4. Characteristics of Patients With Blood Culture–Confirmed Enteric Fever (Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for 
Enteric Fever in Asia Project (SEAP) by Outcome 6 Weeks Following Enrollment—Bangladesh, Nepal, and Pakistan, 2016–2019
 Known Outcomea (n = 8089) Lost to Follow-up (n = 610) Died (n = 6)
Demographics    
 Age, median (IQR), years 8 (4–19) 6 (3–12) 6 (2–33)
 Male gender, n (%) 4622 (57) 356 (58) 4 (67)
Isolate characteristics    
 S. Typhi serovar, n (%) 7037 (87) 548 (90) 6 (100)
 Fluoroquinolone resistance,b n/N (%) 7630/7990 (95) 561/602 (93) 6 (100)
 S. Typhi third-generation cephalosporin resistance,b n/N (%)    
  Bangladesh 0/3797 (0) 0/268 (0) 0/0 (0)
  Nepal 0/1268 (0) 0/80 (0) 0/2 (0)
  Pakistan 1223/1900 (64) 136/192 (71) 4/4 (100)
Severity    
 Time from fever onset to hospital presentation,c median (IQR), days 5 (3–7) 5 (3–7) 8 (4–14)
 Prior antibiotic use,d n/N (%) 3077 (38) 253 (41) 3 (50)
 Hospitalized, n (%) 2600/8056 (32) 199/607 (33) 5 (83)
  Duration of hospital stay,e median (IQR), days 5 (3–7) 6 (3–8) 7 (5–9)
  Complications,e n (%) 81/4732 (1.7) 8/469 (1.7) 1 (17)
N = 8705. 
Abbreviation: IQR, interquartile range.
aDoes not include the 6 patients who died.
bPatients with antimicrobial resistance testing results available.
cIncludes patients from SEAP hospitals only (not laboratory network sites).
dPatient or caregiver reported.
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including laboratory network sites alongside our hospital-based 
surveillance, we were able to more accurately estimate the case-
fatality ratio compared with utilizing tertiary hospitals alone. 
While our overall case-fatality ratio of less than 1% is consider-
ably lower than published estimates, it is comparable to recent 
findings from Dhaka, Bangladesh, that utilized a similar meth-
odology as SEAP and included patients diagnosed through lab-
oratory network sites [20, 21].
Previous studies have reported higher mortality among pa-
tients infected with multidrug-resistant S. Typhi [7–9]. With 
improved clinical services and the use of effective antibiotics, 
case fatality among blood culture–confirmed enteric fever has 
reportedly decreased in recent decades [8, 20, 21]. However, 
with widespread antimicrobial resistance, there is a risk of in-
creased severe outcomes. While we did not detect any ceph-
alosporin resistance in Bangladesh or Nepal [22], a recent 
molecular surveillance study projected that resistance will 
develop in the region because there are documented cases in 
Pakistan and India [12, 23]. All deaths from our population 
were among patients infected with drug-resistant S. Typhi, in-
cluding XDR typhoid among all deaths in Pakistan, highlighting 
the threat that antimicrobial resistance poses to the currently 
low case-fatality ratio.
Similarly, clinical complications attributed to enteric fever 
by treating physicians were infrequently identified among 
SEAP patients. Hepatitis, septic shock, and pulmonary com-
plications—the complications we commonly identified—are 
well documented in the literature [8]. Like the fatal cases, most 
patients with a complication were infected with organisms 
resistant to antibiotics commonly prescribed in the region. 
A study from Vietnam reported complications among an esti-
mated 15% of patients with typhoid and found that clinical com-
plications were associated with intermediate fluoroquinolone 
resistance during a time when these drugs were widely used to 
treat enteric fever [24]. Because we observed that patients with 
third-generation cephalosporin resistance were more likely to 
develop a typhoid-related complication, we anticipate the rates 
of severe disease to increase as this class of antimicrobials, in-
cluding ceftriaxone and cefixime, is commonly prescribed em-
pirically in the SEAP settings [25].
A considerable proportion of blood culture–confirmed en-


















S. Typhi S. Paratyphi A
Figure 1. Proportion of Salmonella Typhi and Salmonella Paratyphi A case-patients enrolled in SEAP who were hospitalized by age in years and by country—Bangladesh, 
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especially among children who would benefit from typhoid 
conjugate vaccines (TCVs), which are safe for children as young 
as 6 months old [26]. Similar to our findings from SEAP, a sur-
veillance study for enteric fever in Bangladesh identified that 
almost 41% of patients with blood culture–confirmed enteric 
fever younger than 2 years old were hospitalized [21]. With the 
introduction of TCVs into routine immunization and improved 
access to safe water, food, and sanitation and hygiene facilities, 
we expect a reduction in typhoid hospitalizations, making hos-
pital beds available for patients requiring inpatient care for 
other conditions [15].
Antibiotics are widely available without prescription in the 
communities under SEAP surveillance. We observed that hospi-
talization was associated with antimicrobial use and resistance, 
especially in Pakistan, which is currently experiencing an on-
going outbreak of XDR typhoid [12]. Delayed care-seeking and 
self-reported prior antibiotic use, while only moderately reliable 
[27], were also associated with higher odds of severe disease, 
consistent with previous findings [8, 28]. Reasons for delayed 
care-seeking are unknown; possibly some patients presented to 
the study sites only after treatment failure, especially in cases of 
drug resistance [29]. Empiric treatment was also common in 
our sites [25]. Such treatment, in addition to indiscriminate an-
tibiotic usage in settings already detecting drug-resistant enteric 
fever, may put patients at risk for poor outcomes due to delays 
in appropriate therapy [4, 11, 30]. Indeed, empiric treatment in 
Pakistan was associated with a longer duration of hospital stay, 
most probably due to ineffective initial treatment. Similarly, pa-
tients from Pakistan with evidence of XDR typhoid were ad-
mitted for approximately 50% longer than those with non-XDR 
typhoid. The longer duration of hospital stay may be attributed 
to morbidity but may also be driven by the need for intravenous 
carbapenem therapy. Typhoid vaccination could potentially re-
duce the overprescribing of antibiotics, the subsequent spread 
Table 5. Univariable and Multivariable Analysis of Factors Associated With Hospitalization Among Patients With Blood Culture–Confirmed Enteric Fever 
(Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for Enteric Fever in Asia Project (SEAP), by Country—Bangladesh, Nepal, and Pakistan, 
September 2016–September 2019














Age in years       
 <2 2.82 (2.21, 3.60)* 5.51 (1.90, 16.01)* 1.74 (.67, 4.53) 3.19 (.41, 24.96) .83 (.62, 1.11) .70 (.48, 1.03)
 2–4 2.17 (1.80, 2.64)* 3.87 (1.35, 11.10)* .76 (.37, 1.55) 2.31 (.75, 7.15) .92 (.72, 1.17) .73 (.53, 1.02)
 5–15 1.61 (1.34, 1.93)* 3.10 (1.08, 8.90)* 1.47 (1.14, 1.89)* 3.10 (2.01, 4.80)* 1.00 (.80, 1.26) .99 (.73, 1.33)
 ≥16 Ref Ref Ref Ref Ref Ref
Gender       
 Female Ref Ref Ref Ref Ref Ref
 Male 1.00 (.88, 1.14) .91 (.78, 1.07) .70 (.55, .86)* .78 (.51, 1.28) 1.09 (.92, 1.29) 1.16 (.93, 1.45)
Species       
 S. Paratyphi A Ref Ref Ref Ref Ref Ref
 S. Typhi 1.67 (1.37, 2.03)* 1.43 (1.10, 1.84)* 1.51 (1.09, 2.11)* 1.58 (.91, 2.74) 2.41 (1.63, 3.56)* 1.70 (1.05, 2.74)*
Fluoroquinolone sensitivity       
 Susceptible Ref Ref Ref Ref Ref Ref
 Reduced susceptibility 1.57 (.93, 2.63) 2.64 (1.27, 5.48)* .88 (.64, 1.22) .84 (.45, 1.59) 2.84 (1.81, 4.47)* 1.98 (1.18, 3.32)*
Third-generation cephalosporin 
sensitivityb
      
 Susceptible Ref Ref Ref Ref Ref Ref
 Resistant … … … … 2.07 (1.74, 2.47)* 1.78 (1.40, 2.27)*
Prior antibiotic use       
 No Ref Ref Ref Ref Ref Ref
 Yes 1.75 (1.53, 1.99)* 1.32 (1.12, 1.56)* 1.62 (1.27, 2.07)* 1.33 (.61, 2.00) 1.78 (1.50, 2.11)* 2.05 (1.62, 2.58)*
Days from fever onset to hospital 
presentationc
      
 <3 days Ref Ref Ref Ref Ref Ref
 3–5 days 1.14 (.87, 1.49) 1.11 (.85, 1.46) 1.17 (.67, 2.06) 1.10 (.61, 2.00) .68 (.42, 1.07) .61 (.38, .99)*
 6–9 days 2.04 (1.55, 2.69)* 1.87 (1.40, 2.47)* 2.86 (1.56, 5.25)* 2.53 (1.32, 4.85)* 1.53 (.97, 2.43) 1.17 (.72, 1.90)
 ≥10 days 2.70 (1.89, 3.87)* 2.55 (1.76, 3.69)* 2.46 (1.21, 5.01)* 2.31 (1.08, 4.92)* 3.67 (2.27, 5.93)* 2.47 (1.50, 4.14)*
Data are presented as ORs (95% CI). *P < .05. 
Abbreviations: CI, confidence interval; OR, odds ratio; Ref, reference.
aMultivariable models include patients recruited from SEAP hospitals only.
bCephalosporin resistance only detected in Pakistan.
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of antimicrobial resistance [26], and the overall burden on the 
healthcare system.
An important limitation to our study is the potential to miss 
the most severe cases of enteric fever. To ascertain complica-
tions, data were abstracted from medical records of blood cul-
ture–confirmed patients who sought care at the SEAP hospitals. 
However, most patients with enteric fever likely seek care at 
pharmacies or informal care systems and never present to hos-
pitals [31]. We may have missed severe disease and enteric fever 
deaths among those who did not present to a hospital or who 
did not obtain diagnostic tests, as these are costly and not al-
ways required before treatment [15, 16]. Nevertheless, we were 
able to review over 5000 medical records of blood culture–con-
firmed cases. We may have missed deaths among patients lost 
to follow up, especially patients in Pakistan with XDR typhoid 
infections who would be more likely to have severe outcomes, 
including death. While our loss to follow-up was low, our es-
timated case-fatality ratio is likely biased downwards. Because 
it may be more difficult to contact families of individuals who 
died, those reached for follow-up may not be representative of 
the true case-fatality ratio. However, our hospitalization esti-
mates—an important measure of severity—may be overesti-
mated because we calculated the proportion hospitalized only 
among those patients with enteric fever presenting to a hos-
pital or laboratory network site, which does not consider the 
large proportion of cases who seek care at pharmacies or other 
clinics, especially those with mild disease. Last, blood culture 
sensitivity is estimated to be approximately 60%—or lower for 
Table 6. Univariable and Multivariable Analysis of Factors Associated With Duration of Hospital Stay Among Hospitalized Patients With Blood Culture–
Confirmed Enteric Fever (Salmonella Typhi and Paratyphi A) Enrolled in the Surveillance for Enteric Fever in Asia Project (SEAP), by Country—Bangladesh, 
Nepal, and Pakistan, September 2016–September 2019














Age in years       
 <2 1.00 (.63, 1.58) 1.00 (.63, 1.58) 1.47 (.94, 2.31) 1.61 (.95, 2.73) .99 (.84, 1.17) .96 (.82, 1.12)
 2–4 .97 (.62, 1.53) .98 (.62 1.55) 1.52 (1.08, 2.16)* 1.53 (1.09, 2.15)* 1.10 (.97, 1.25) 1.04 (.92, 1.18)
 5–10 1.06 (.67, 1.67) 1.06 (.67, 1.67) 1.46 (1.27, 1.68)* 1.46 (1.27, 1.68)* 1.05 (.94, 1.80) 1.05 (.94, 1.17)
 ≥16 Ref Ref Ref Ref Ref Ref 
Gender       
 Female Ref Ref Ref Ref Ref Ref 
 Male 1.01 (.95, 1.07) 1.01 (.95, 1.07) .97 (.84, 1.13) .91 (.79, 1.04) 1.03 (.94, 1.13) 1.10 (1.00, 1.20)*
Serovar       
  S. Paratyphi A Ref Ref Ref Ref Ref Ref 
  S. Typhi 1.08 (.98, 1.20) 1.08 (.97, 1.19) 1.30 (1.04, 1.63)* 1.27 (1.03, 1.57)* 1.09 (.87, 1.37) 1.02 (.79, 1.33)
Fluoroquinolone sensitivity       
 Susceptible Ref Ref Ref Ref Ref Ref 
 Reduced susceptibility .77 (.58, 1.01) .76 (.57, 1.00a)* .85 (.69, 1.05) .86 (.71, 1.04) 1.26 (.93, 1.69) 1.00 (.75, 1.34)
Third-generation cephalosporin 
sensitivityb
      
 Susceptible Ref Ref Ref Ref Ref Ref 
 Resistant … … … … 1.48 (1.34, 1.64)* 1.54 (1.39, 1.72)*
Prior antibiotic use       
  No Ref Ref Ref Ref Ref Ref 
  Yes 1.01 (.95, 1.07) 1.01 (.95, 1.07) 1.08 (.93, 1.25) 1.12 (.97, 1.29) .98 (.88, 1.08) 1.06 (.95, 1.18)
Empirically treated       
  No Ref Ref Ref Ref Ref Ref 
  Yes .99 (.92, 1.06) .99 (.92, 1.06) .89 (.74, 1.06) 1.02 (.86, 1.20) 1.27 (1.15, 1.42)* 1.22 (1.10, 1.35)*
Days from fever onset to hospital 
presentation
      
 <3 days Ref Ref Ref Ref Ref Ref 
 3–5 days .97 (.87, 1.08) .97 (.87, 1.09) .85 (.68, 1.07) .77 (.62, .96)* 1.06 (.84, 1.33) .99 (.79, 1.24)
 6–9 days .98 (.88, 1.09) .98 (.87, 1.09) .94 (.75, 1.18) .83 (.66, 1.03) .94 (.75, 1.18) .86 (.69, 1.08)
 ≥10 days .91 (.79, 1.03) .89 (.77, 1.02) .89 (.68, 1.17) .79 (.62, 1.02) .96 (.77, 1.21) .85 (.68, 1.07)
Data are presented as RRs (95% CI). *P < .05. 
Abbreviations: CI, confidence interval; Ref, reference; RR, relative risk.
aRounding: .76 (.57, .9985); P = .0488.
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those with prior antibiotic use [32]. Therefore, we likely missed 
additional enteric fever cases presenting to our study sites who 
were not confirmed by blood culture, including patients with 
enteric fever–related intestinal perforations [33]. Future sur-
veillance should prioritize reducing the loss to follow-up of 
blood culture–confirmed cases to improve the accuracy of case 
fatality and severe disease estimates.
Conclusions
While clinical complications and deaths were rarely identified in 
our large dataset, the high proportion of hospitalizations and pro-
longed hospital stays, reflecting substantial costs and morbidity, 
underscores the benefit of immediate interventions. Case fatality 
from enteric fever is not a static figure; it varies according to 
context and time. We found a lower-than-expected case-fatality 
ratio but noted that extensive drug resistance is associated with 
more severe disease and morality, and global data demonstrate a 
continuing trend in the emergence and spread of drug-resistant 
strains. Thus, continuing to monitor enteric fever mortality is 
important and can be added to existing hybrid surveillance at 
a low marginal cost. The World Health Organization’s Strategic 
Advisory Group of Experts (SAGE) on Immunization has re-
commended TCV introduction in countries with a high burden 
of typhoid fever or with a high burden of antimicrobial-resistant 
S. Typhi, both scenarios applicable at the SEAP sites [34]. Patient 
outcomes, disease severity, and the impact of antimicrobial re-
sistance should drive decision making on enteric fever inter-
ventions, including vaccine deployment. With support from 
Gavi, the Vaccine Alliance to introduce TCVs, more countries 
will need reliable burden data for vaccine implementation. It is 
also important to note that there is an identified burden of S. 
Paratyphi A,  which is not covered by the current vaccines, fur-
ther emphasizing the need to monitor trends in disease burden 
and severity among patients with enteric fever.
Notes
Acknowledgments. The authors thank all involved in the Surveillance 
for Enteric Fever in Asia Project, especially the research staff and study 
participants.
Disclaimer. The findings and conclusions in this study are those of the 
authors and do not necessarily reflect the position of the Centers for Disease 
Control and Prevention. 
Financial support. This work was supported by the Bill & Melinda Gates 
Foundation (grant number OPP1113007, INV-008335) and an agreement 
(subcontract/subgrant) between the Sabin Vaccine Institute (primary 
grantee for the Surveillance for Enteric Fever in Asia Project grant from the 
Bill & Melinda Gates Foundation) and the CDC Foundation.
Supplement sponsorship. This supplement is sponsored by the Sabin 
Vaccine Institute and made possible by a grant from the Bill & Melinda 
Gates Foundation.
Potential conflicts of interest. I.  I. B.  reports consulting fees from 
BlueDot, outside the submitted work. S.  K. S.  reports grants from Child 
Health Research Foundation. All other authors report no potential conflicts. 
All authors have submitted the ICMJE Form for Disclosure of Potential 
Conflicts of Interest. Conflicts that the editors consider relevant to the con-
tent of the manuscript have been disclosed.
References
1. Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income 
and middle-income countries: a systematic, literature-based update with risk-
factor adjustment. Lancet Glob Health 2014; 2:e570–80.
2. Stanaway JD, Reiner RC, Blacker BF, et al. The global burden of typhoid and para-
typhoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. 
Lancet Infect Dis 2019; 19: 369–81.
3. Deen  J, von  Seidlein  L, Andersen  F, Elle  N, White  NJ, Lubell  Y. Community-
acquired bacterial bloodstream infections in developing countries in south and 
southeast Asia: a systematic review. Lancet Infect Dis 2012; 12:480–7.
4. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 
2002; 347:1770–82.
5. Crump  JA, Sjölund-Karlsson  M, Gordon  MA, Parry  CM. Epidemiology, clin-
ical presentation, laboratory diagnosis, antimicrobial resistance, and antimicro-
bial management of invasive salmonella infections. Clin Microbiol Rev 2015; 
28:901–37.
6. Crump JA, Ram PK, Gupta SK, Miller MA, Mintz ED. Part I. Analysis of data gaps 
pertaining to Salmonella enterica serotype Typhi infections in low and medium 
human development index countries, 1984–2005. Epidemiol Infect 2008; 136: 
436–48.
7. Qamar  FN, Azmatullah  A, Bhutta  ZA. Challenges in measuring complica-
tions and death due to invasive Salmonella infections. Vaccine 2015; 33(Suppl 
3):C16–20.
8. Azmatullah A, Qamar FN, Thaver D, Zaidi AK, Bhutta ZA. Systematic review of 
the global epidemiology, clinical and laboratory profile of enteric fever. J Glob 
Health 2015; 5:020407.
9. Pieters Z, Saad NJ, Antillón M, Pitzer VE, Bilcke  J. Case fatality rate of enteric 
fever in endemic countries: a systematic review and meta-analysis. Clin Infect Dis 
2018; 67:628–38.
10. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World 
Health Organ 2004; 82:346–53.
11. Zaki  SA, Karande  S. Multidrug-resistant typhoid fever: a review. J Infect Dev 
Ctries 2011; 5:324–37.
12. Klemm EJ, Shakoor S, Page AJ, et al. Emergence of an extensively drug-resistant 
salmonella enterica Serovar Typhi clone harboring a promiscuous plasmid 
encoding resistance to fluoroquinolones and third-generation cephalosporins. 
MBio 2018; 9:e00105–18.
13. Carter A, Garrett DO. Introducing typhoid conjugate vaccine in South Asia: les-
sons learned from the surveillance for enteric fever in Asia project. Clin Infect 
Dis. Manuscript in preparation, in this supplement.
14. Barkume C, Date K, Saha SK, et al. Phase I of the Surveillance for Enteric Fever 
in Asia Project (SEAP): an overview and lessons learned. J Infect Dis 2018; 
218:188–94.
15. Saha  S, Santosham  M, Hussain  M, Black  RE, Saha  SK. Rotavirus vaccine will 
improve child survival by more than just preventing diarrhea: evidence from 
Bangladesh. Am J Trop Med Hyg 2018; 98:360–3.
16. Luby SP, Saha S, Andrews JR. Towards sustainable public health surveillance for 
enteric fever. Vaccine 2015; 33(Suppl 3):C3–7.
17. Saha SK, Baqui AH, Hanif M, et al. Typhoid fever in Bangladesh: implications for 
vaccination policy. Pediatr Infect Dis J 2001; 20:521–4.
18. Vollaard AM, Ali S, van Asten HA, et al. Risk factors for typhoid and paratyphoid 
fever in Jakarta, Indonesia. JAMA 2004; 291:2607–15.
19. Saha S, Islam M, Saha S, et al. Designing comprehensive public health surveillance 
for enteric fever in endemic countries: importance of including different health-
care facilities. J Infect Dis 2018; 218:227–31.
20. Yu AT, Amin N, Rahman MW, Gurley ES, Rahman KM, Luby SP. Case-fatality 
ratio of blood culture-confirmed typhoid fever in Dhaka, Bangladesh. J Infect Dis 
2018; 218:222–6.
21. Saha S, Islam MS, Sajib MSI, et al. Epidemiology of typhoid and paratyphoid: im-
plications for vaccine policy. Clin Infect Dis 2019; 68:117–23.
22. Qamar  FN, Saha  S. Antimicrobial resistance in typhoidal Salmonella from 3 
Asian countries: surveillance of enteric fever in Asia (2016–2019). Clin Infect Dis. 
Manuscript in preparation, in this supplement.
23. Britto CD, Dyson ZA, Duchene S, et al. Laboratory and molecular surveillance of 
paediatric typhoidal Salmonella in Nepal: antimicrobial resistance and implica-
tions for vaccine policy. PLoS Negl Trop Dis 2018; 12:e0006408.
24. Parry CM, Thompson C, Vinh H, et al. Risk factors for the development of severe 







ent_3/S222/6013556 by guest on 26 January 2021
Severity and Outcomes of Enteric Fever • cid 2020:71 (Suppl 3) • S231
25. Hemlock  C, Bogoch  I. Utilization of blood culture in South Asia for the diagnosis 
and treatment of febrile illness. Clin Infect Dis. Manuscript in preparation, in this 
supplement.
26. Andrews JR, Baker S, Marks F, et al. Typhoid conjugate vaccines: a new tool in the 
fight against antimicrobial resistance. Lancet Infect Dis 2019; 19:e26–30.
27. Vaidya K, Andrews J. Antibiotic use prior to hospital presentation among individ-
uals with suspected enteric fever in Nepal, Bangladesh, and Pakistan. Clin Infect 
Dis. Manuscript in preparation, in this supplement.
28. Bhutta ZA. Impact of age and drug resistance on mortality in typhoid fever. Arch 
Dis Child 1996; 75:214–7.
29. Bhutta ZA, Naqvi SH, Razzaq RA, Farooqui BJ. Multidrug-resistant typhoid in 
children: presentation and clinical features. Rev Infect Dis 1991; 13:832–6.
30. Kadhiravan  T, Wig  N, Kapil  A, Kabra  SK, Renuka  K, Misra  A. Clinical out-
comes in typhoid fever: adverse impact of infection with nalidixic acid-resistant 
Salmonella typhi. BMC Infect Dis 2005; 5:37.
31. Andrews J, Qamar FN. Healthcare utilization patterns for acute febrile illness in 
Bangladesh, Nepal, and Pakistan: Surveillance for Enteric Fever in Asia Project. 
Clin Infect Dis. Manuscript in preparation, in this supplement.
32. Antillon M, Saad NJ, Baker S, Pollard AJ, Pitzer VE. The relationship between 
blood sample volume and diagnostic sensitivity of blood culture for typhoid 
and paratyphoid fever: a systematic review and meta-analysis. J Infect Dis 
2018; 218:255–67.
33. Qazi SH, Qamar FN. Healthcare utilization patterns for acute febrile illness 
in Bangladesh, Nepal and Pakistan: Surveillance for Enteric Fever in Asia 
Project. Clin Infect Dis. Manuscript in preparation, in this supplement.
34. Strategic Advisory Group of Experts in Immunization. Summary of the 
October 2017 meeting of the Strategic Advisory Group of Experts in 
Immunization. Available at: https://www.who.int/immunization/policy/








ent_3/S222/6013556 by guest on 26 January 2021
